Trade
Transgene Biotek share price
Extreme risk
You have to be logged in to add this to Watchlist.- ₹2.95(-3.91%)July 14, 2026 15:51:22 PM IST
- NSE
- BSE
- Vol : 47.80 K (NSE + BSE)Last 20 day avg : 37.84 K
Transgene Biotek is trading -3.91% lower at Rs 2.95 as compared to its last closing price. Transgene Biotek has been trading in the price range of 3.18 & 2.81. Transgene Biotek has given -2.54% in this year & 0.00% in the last 5 days. The company posted a net profit of -0.46 Crores in its last quarter.Listed peers of Transgene Biotek include Sun Pharmaceutical Industries (0.84%), Torrent Pharmaceuticals (0.43%), Divi's Laboratories (3.64%).The Mutual Fund holding in Transgene Biotek was at -% in . The MF holding has - from the last quarter. The FII holding in Transgene Biotek was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 14, 2026, 07:59 PM UTC
- BetaHigh volatility1.75Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- Debt To Equity-The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Transgene Biotek Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,940.15 | 0.84 | 4,65,496.01 | 38.61 | 6.15 | 0.89 | 0.50 |
| Torrent Pharmaceuticals | 4,969.50 | 0.43 | 1,68,183.71 | 76.52 | 19.43 | 0.80 | 17.62 |
| Divi's Laboratories | 7,185.20 | 3.64 | 1,90,956.56 | 81.09 | 11.89 | 0.45 | 0.01 |
| Lupin | 2,469.45 | -1.13 | 1,13,490.62 | 33.37 | 6.48 | 0.49 | 11.80 |
| Cipla | 1,438.55 | 0.82 | 1,16,155.60 | 20.93 | 3.53 | 0.95 | 0.81 |
Transgene Biotek Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-29 | Audited Results |
| 2026-02-13 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
| 2025-08-07 | Quarterly Results |
| 2025-05-07 | Audited Results |
About the company Transgene Biotek
- IndustryBiotechnology & Drugs
- ISININE773D01018
- BSE Code526139
- NSE Code
Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
Transgene Biotek Share Price FAQs
Transgene Biotek is trading at 2.95 as on Tue Jul 14 2026 10:21:22. This is -3.91% lower as compared to its previous closing price of 3.07.
The market capitalization of Transgene Biotek is 19.40 Cr as on Tue Jul 14 2026 10:21:22.
The 52 wk high for Transgene Biotek is 5.26 whereas the 52 wk low is 1.83
Transgene Biotek can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: -
- Dividend Yield: 0.00%
- D/E ratio: 2.05
Transgene Biotek reported a net profit of -1.65 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Transgene Biotek QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.